MacDonaldKPotvinK. Interprovincial variation in Canadians' access to publicly funded pharmaceuticals. CPJ2004;137(7):29.
2.
AnisAHGuhDWangX-H. A dog's breakfast: prescription drug coverage varies widely across Canada. Med Care2001;39(4):315–26.
3.
GregoireJPMacNeilPSkiltonKInter-provincial variation in government drug formularies. Can J Public Health2001;92:307–12.
4.
DonabedianA. The quality of care: how can it be assessed?JAMA1988;260(12):1743–8.
5.
ForsterAJClarkHDMenardA. Adverse events among medical patients after discharge from hospital. CMAJ2004;170(3):345–9.
6.
LaupacisAAndersonGO'BrienB. Drug policy: making effective drugs available without bankrupting the healthcare system. Healthcare Papers2002;3(1):12–30.
7.
MacKinnonNJKumarR. Prior authorization programs: a critical review of the literature. J Managed Care Pharm2001;7(4):297–302.
8.
HornSDSharkeyPDTracyDMIntended and unintended consequences of HMO cost-containment strategies: results from the Managed Care Outcomes Project. Am J Manag Care1996;2:253–64.
9.
HeplerCD. Where is the evidence for formulary effectiveness?Am J Health-Syst Pharm1997;54:95.
10.
KozmaCMReederCELingleEW. Expanding Medicaid drug formulary coverage: effects on utilization of related services. Med Care1990;28:963–977.
11.
TamblynRLapriseRHanleyJAAdverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA2001;285(4):421–9.
12.
FelixS. Claims frustrations continue to grow. Pharmacy Post. June 2003;29.
13.
MacKinnonNJ. How much evidence is enough? A commentary on SCRIP and pharmacy practice research in Canada. CPJ2002;135:25–9.
14.
WeingartenSRHenningJMBadamgaravEInterventions used in disease management programmes for patients with chronic illness — which ones work? Meta-analysis of published reports. BMJ2002;325:925–33.
